Eric R Kandel, 94435 Riverside Dr APT 52, New York, NY 10025

6509190, Jan 21, 2003

Nov 12, 1997

08/969137

Eric R. Kandel - Riverdale NY
Mark Mayford - San Diego CA

The Trustees of Columbia University in the City of New York - New York NY

C07H 2102

435354, 435325, 435352, 536 231, 536 235, 536 241

The present invention provides for a recombinant DNA construct for expressing a gene of interest comprising a mouse calcium-calmodulin-dependent kinase IIÃ promoter operatively linked to a gene of interest. The present invention also provides for a murine neuronal cell line which has been stably transformed with the recombinant DNA construct.

6551821, Apr 22, 2003

Dec 23, 1997

08/997685

Eric R. Kandel - Riverdale NY
Bina Santoro - Roma, IT
Dusan Bartsch - New York NY
Steven Siegelbaum - New York NY
Gareth Tibbs - New York NY
Seth Grant - Edinburgh, GB

The Trustees of Columbia University in the City of New York - New York NY

C07H 2104

435325, 43525233, 4353201, 514 44, 536 231, 536 235

The present invention provides an isolated nucleic acid molecule encoding a brain cyclic nucleotide gated ion channel (BCNG) protein. An isolated BCNG protein is also provided as is a composition comprising a BCNG encoding nucleic acid or protein or a portion thereof. The present invention also provides a method of identifying an ion channel subunit related protein encoding nucleic acid molecule in a sample. The invention further provides a method for evaluating the ability of a compound to modulate an ion channel associated neurological, cardia, or renal condition. The invention also provides a method for evaluating the ability of a compound to interact with a BCNG-related ion channel subunit protein. Additionally, the present invention provides a method for identifying a compound capable of modulating the activity of a BCNG-related protein. The present invention additionally provides a method of treating a cardiac, renal or neurological condition.

6703485, Mar 9, 2004

May 28, 1998

09/086436

Eric R. Kandel - Riverdale NY
Bina Santoro - Rome, IT
Dusan Bartsch - New York NY
Steven Siegelbaum - New York NY
Gareth Tibbs - New York NY
Seth Grant - Edinburgh, GB

The Trustees of Columbia University in the City of New York - New York NY

C07K 100

530350, 435 6, 435325, 435354, 435366, 435375, 536 231

The present invention provides an isolated nucleic acid encoding a BCNG protein or a portion thereof or BCNG-related protein or a portion thereof. The present invention further provides a method for identifying a nucleic acid in a sample which encodes a BCNG protein or a BCNG-related protein. The present invention also provides a method for testing whether a compound affects the expression of a BCNG protein or a BCNG-related protein. In addition, the present invention further provides a method for identifying a compound capable of interacting with a BCNG protein or a BCNG-related protein. Also, the present invention provides a method for identifing a compound capable of modulating BCNG protein or BCNG-related protein activity. Further, the present invention also provides a method of treating a condition in a subject which comprises administering to the subject an amount of the provided compound, effective to treat the condition.

7015190, Mar 21, 2006

Jun 3, 1996

08/656811

Dusan Bartsch - New York NY, US
Eric R. Kandel - Riverdale NY, US
Mirella Ghirardi - Turin, IT

The Trustees of Columbia University in the City of New York - New York NY

A61K 38/00
A61K 48/00

514 2, 514 44

The present invention provides for a method to enhance long-term memory in a subject whose cAMP-responsive gene expression is repressed due to binding of a cAMP-response-element-binding-protein-2 to a protein or a DNA associated with cAMP-responsive gene expression, or both, which comprises administering to the subject a compound capable of interfering with such binding in an amount effective to interfere with binding of the protein or the DNA so as to thereby derepress cAMP-responsive gene expression in the subject and enhance the subject's long-term memory.

7635768, Dec 22, 2009

Jan 14, 2003

10/341999

Eric R. Kandel - Riverdale NY, US
Mark Mayford - San Diego CA, US

The Trustees of Columbia University in the City of New York - New York NY

C07H 21/04
C07H 21/02

536 241, 536 231

A recombinant nucleic acid comprising nucleotides corresponding to a 3. 2 kb 3′ untranslated region present in mouse calcium calmodulin kinase II alpha subunit-encoding mRNA is provided. An isolated nucleic acid which hybridizes to the 3′ untranslated region of mouse calcium calmodulin kinase II alpha subunit-encoding mRNA under conditions comprising two post-hybridization washes of 15 minutes each at 42 C. in 0. 2× standard sodium citrate buffer is also provided.

2002012, Sep 12, 2002

Aug 17, 1998

09/135521

ISABELLE M. MANSUY - PARAMUS NJ, US
DANNY G. WINDER - NEW YORK NY, US
MARK MAYFORD - SAN DIEGO CA, US
MARY ELIZABETH BACH - BRONX NY, US
ERIC R. KANDEL - RIVERDALE NY, US

A61K048/00
G01N033/567
A01K067/00

800/003000, 514/044000, 514/002000, 435/007210

The present invention provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes calcineurin or a variant thereof under the control of a regulatable promoter, introduced into the mammal, or an ancestor thereof, at an embryonic stage. The present invention also provides for a method of evaluating whether a compound is effective in improving long-term memory in a subject suffering from impaired long-term memory which comprises: (a) administering the compound to the transgenic nonhuman mammal of claim 1 wherein the mammal has increased brain-specific calcineurin activity due to expression of the nucleic acid, and (b) comparing the long-term memory of the mammal in step (a) with the long-term memory of the mammal in the absence of the compound so as to determine whether the compound is effective in rescuing the long-term memory defect in the subject.

2002017, Nov 14, 2002

Mar 5, 2002

10/091714

Isabelle Mansuy - Mulhouse, FR
Eric Kandel - Riverdale NY, US

A01K067/027
C12N015/85
C12N005/06

800/008000, 800/014000, 435/455000, 435/325000, 435/320100

The present invention provides a transgenic nonhuman mammal and mammalian cells whose genomes encode a calcineurin inhibitor. The expression of the inhibitor is targeted to the forebrain and may be induced experimentally. The present invention further provides a composition of matter comprising the nucleic acid sequences encoding the inhibitor and additional sequences required for its targeted expression and regulation. In addition, the present invention provides methods for determining whether an agent inhibits long-term potentiation and/or learning and memory in a mammal.

2003014, Jul 24, 2003

Jan 27, 2003

10/352281

Isabelle Mansuy - Mulhouse, FR
Danny Winder - New York NY, US
Mary Bach - Bronx NY, US
Eric Kandel - Riverdale NY, US
Mark Mayford - San Diego CA, US

The Trustees of Columbia University in the City of New York - New York NY

A01K067/027

800/014000, 800/015000, 800/016000, 800/017000, 800/018000, 800/003000

The present invention provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes calcineurin or a variant thereof under the control of a regulatable promoter, introduced into the mammal, or an ancestor thereof, at an embryonic stage. The present invention also provides for a method of evaluating whether a compound is effective in improving long-term memory in a subject suffering from impaired long-term memory which comprises: (a) administering the compound to the transgenic nonhuman mammal of claim 1 wherein the mammal has increased brain-specific calcineurin activity due to expression of the nucleic acid, and (b) comparing the long-term memory of the mammal in step (a) with the long-term memory of the mammal in the absence of the compound so as to determine whether the compound is effective in rescuing the long-term memory defect in the subject.